- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Disease-modifying treatments in Alzheimer’s disease ; volume:270 ; number:4 ; day:16 ; month:2 ; year:2023 ; pages:2342-2344 ; date:4.2023
Journal of neurology ; 270, Heft 4 (16.2.2023), 2342-2344, 4.2023
- Urheber
-
Edwards, Marc
Corkill, Robin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-023-11602-8
- URN
-
urn:nbn:de:101:1-2023080721092848919334
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Edwards, Marc
- Corkill, Robin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy